Seres Therapeutics Inc

NASDAQ:MCRBUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Ratings actions from Benzinga: https://www.benzinga.com/quote/MCRB/analyst-ratings

(END) Dow Jones Newswires

November 14, 2024 11:20 ET (16:20 GMT)

shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 170 135 Additional paid-in capital 986,211 933,244 Accumulated other comprehensive loss -- -- Accumulated deficit (962,462) (978,235) ----------- ---------- Total stockholders' equity (deficit) 23,919 (44,856) ----------- ---------- Total liabilities and stockholders' equity (deficit) $ 178,742 $ 358,600 =========== ========== ([1]) Includes $38,877 as of December 31, 2023 of milestones related to the construction of the Company's dedicated manufacturing suite at BacThera AG, or Bacthera. ([2]) Includes related party amount of $35,783 at December 31, 2023. SERES THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited, in thousands, except share and per share data) Three Months Ended Nine Months Ended September 30, September 30, --------------------------- --------------------------- 2024 2023 2024 2023 ------------ ------------ ------------ ------------ Operating expenses: Research and development expenses 16,460 25,154 $ 51,759 94,554 General and administrative expenses 12,710 19,432 $ 40,721 63,519 Total operating expenses 29,170 44,586 $ 92,480 158,073 ----------- ----------- ----------- ----------- Loss from operations (29,170) (44,586) $ (92,480) (158,073) ----------- ----------- ----------- ----------- Other income (expense): Interest income 652 2,572 $ 3,530 5,330 Interest expense -- -- $ -- (2,468) Other (expense) income (22,517) 999 $ (21,184) (202) ----------- ----------- ----------- ----------- Total other (expense) income, net (21,865) 3,571 $ (17,654) 2,660 ----------- ----------- ----------- ----------- Net loss from continuing operations $ (51,035) $ (41,015) $ (110,134) $ (155,413) Net income (loss) from discontinued operations, net of tax $ 139,811 $ (6,839) $ 125,907 $ 82,937 ----------- ----------- ----------- ----------- Net income (loss) $ 88,776 $ (47,854) $ 15,773 $ (72,476) =========== =========== =========== =========== Net loss from continuing operations per share attributable to common stockholders, basic and diluted $ (0.33) $ (0.32) $ (0.73) $ (1.22) Net income (loss) from discontinued operations per share attributable to common stockholders, basic and diluted $ 0.92 $ (0.05) $ 0.84 $ 0.65 Net income (loss) per share attributable to common stockholders, basic and diluted $ 0.58 $ (0.37) $ 0.11 $ (0.57) =========== =========== =========== =========== Weighted average common shares outstanding, basic 152,648,238 128,289,871 150,097,482 127,297,667 Weighted average common shares outstanding, diluted 152,648,238 128,289,871 150,097,482 127,297,667 =========== =========== =========== =========== Other comprehensive income: Unrealized income on investments, net of tax of $0 -- -- -- 10 Currency translation adjustment -- 1 -- 2 ----------- ----------- ----------- ----------- Total other comprehensive income -- 1 -- 12 ----------- ----------- ----------- ----------- Comprehensive income (loss) $ 88,776 $ (47,853) $ 15,773 $ (72,464) =========== =========== =========== ===========